ChromaCode is at the forefront of genomic technology with its innovative High-Definition PCR (HDPCR™) multiplexing platform, which significantly enhances molecular profiling capabilities for oncology and genomics. This platform allows for over four times the multiplexing capacity compared to conventional digital PCR (dPCR), enabling comprehensive coverage of clinically relevant biomarkers. The HDPCR technology is designed to deliver rapid results—typically within 24 hours—with minimal hands-on time required from laboratory personnel. This efficiency is further supported by the ChromaCode Cloud, which automates data interpretation and facilitates a streamlined workflow, making it accessible and cost-effective for lab partners.

The HDPCR platform is particularly beneficial for applications such as tumor profiling, minimal residual disease (MRD) testing, and disease monitoring. It offers a customizable solution that can be tailored for pharmaceutical applications, providing comparable sensitivity to next-generation sequencing (NGS) at a lower cost. With the potential to serve millions of patients annually, ChromaCode's technology not only improves patient management through timely and accurate testing but also supports scalability and broad regulatory compliance, ensuring that lab partners can achieve high margins while maintaining quality and efficiency in their operations.

United States

ChromaCode is deploying a solution for mid-density, multiplexed analysis, high-definition PCR or HDPCR​.COVID-19: EUA (06/2020) for its HDPCR SARS-CoV-2 Real-Time PCR

ChromaCode

Company Details